A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors

Summary

This is an open-label, single-arm study to evaluate the safety and efficacy of multiple doses of SapRNA™-MICA/B Tumor Vaccine in patients with advanced solid tumors. Eligible patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively. Follow-up visits will be performed as scheduled after the end of treatment.

Timeline

Start

2024-11-08

Primary completion

2025-09-01

Completion

2025-12-01

Drugs

Indications